Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 65 years old
- People who have been diagnosed with a type of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL), including a subtype called ETP-ALL
- People whose cancer has not fully cleared at a very detailed level (called MRD-positive, meaning a small number of cancer cells are still detectable by a specialised blood/bone marrow test) after two rounds of initial chemotherapy, while still being in first remission
- People whose cancer cells test positive for a protein called CD38
- People who are well enough to carry out basic daily activities, as rated by their doctor on a standard scale (ECOG score of 0, 1, or 2)
- People whose liver is functioning within acceptable levels, based on specific blood test results (confirm with trial site)
- People who are willing and able to sign a consent form agreeing to take part in the trial
- People who had cancer cells detected in their spinal fluid at the start, but whose spinal fluid has since tested clear
Who may not be able to join:
- People diagnosed with a related condition called T-cell lymphoblastic lymphoma (T-LBL) that has not spread to the bone marrow
- People who still have cancer cells detected in their spinal fluid after two rounds of initial chemotherapy, or who have cancer involvement in the testicles
- People who have breathing difficulties due to a blocked or narrowed airway, as assessed by their treating doctor
- People who currently have an active infection anywhere in the body, as assessed by their treating doctor
- People with serious heart disease (classified as NYHA Class III or IV), or whose heart is pumping at less than 40% of its normal capacity
- People who are HIV positive
- People who are pregnant or currently breastfeeding
- People who test positive for hepatitis B (either the surface antigen or active virus in the blood)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sumeet Mirgh, MD, DM, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre
Phone: 91-8130140245
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MRD negativity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.